Publications by authors named "Steven D Kahl"

Claim this Profile
S
Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Joseph D Ho, Matthew R Lee, Charles T Rauch, Kristen Aznavour, Jonathan S Park, Steven D Kahl

Biochim Biophys Acta Gen Subj· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery.
Nathan P Coussens, G Sitta Sittampalam, Rajarshi Guha, Kyle Brimacombe, Abigail Grossman, Steven D Kahl

Clin Transl Sci· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for GPR40 allosteric agonism and incretin stimulation.
Joseph D Ho, Betty Chau, Logan Rodgers, Frances Lu, Kelly L Wilbur, Steven D Kahl

Nat Commun· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
Chafiq Hamdouchi, Pranab Maiti, Alan M Warshawsky, Amy C DeBaillie, Keith A Otto, Steven D Kahl

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin exits skeletal muscle capillaries by fluid-phase transport.
Ian M Williams, Francisco A Valenzuela, Steven D Kahl, Doraiswami Ramkrishna, Adam R Mezo

J Clin Invest· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, Guemalli R Cardona, Richard W Zink

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes.
Yanyun Chen, Min Song, Jonathan P Riley, Charlie C Hu, Xianbu Peng, Steven D Kahl

Pharmacol Res Perspect· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
Rebecca A Owens, Ryan J Hansen, Steven D Kahl, Chen Zhang, Xiaoping Ruan

J Pharmacol Exp Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.
Miguel A Toledo, Concepción Pedregal, Celia Lafuente, Nuria Diaz, Maria Angeles Martinez-Grau, Steven D Kahl

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Linda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, Elizabeth L Eberle, Jamie H McKinzie, Steven D Kahl

Neuropharmacology· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.
Concepción Pedregal, Elizabeth M Joshi, Miguel A Toledo, Celia Lafuente, Nuria Diaz, Steven D Kahl

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.
Charles H Mitch, Steven J Quimby, Nuria Diaz, Concepcion Pedregal, Marta G de la Torre, Steven D Kahl

J Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.
Cynthia D Jesudason, James E Baker, Robert D Bryant, Jack W Fisher, Libbey S O'Farrell, Steven D Kahl

ACS Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists.
Liang Zeng Yan, Hansen M Hsiung, Mark L Heiman, Robert A Gadski, Paul J Emmerson, Steven D Kahl

Curr Top Med Chem· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.
Wayne D Kohn, Radmila Micanovic, Sharon L Myers, Andrew M Vick, Steven D Kahl

Peptides· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold.
Liang Z Yan, David Flora, Patrick Edwards, David L Smiley, Paul J Emmerson, Steven D Kahl

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a beta-MSH-derived MC-4R selective agonist.
John P Mayer, Hansen M Hsiung, David B Flora, Patrick Edwards, Dennis P Smith, Steven D Kahl

J Med Chem· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scintillation proximity assay.
Steven D Kahl, Christian C Felder

Curr Protoc Neurosci· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor.
Timothy I Richardson, Paul L Ornstein, Karin Briner, Matthew J Fisher, Ryan T Backer, Steven D Kahl

J Med Chem· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis